Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical & Clinical Drug Development

Bio-Rad Laboratories, Inc. recently extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of six antibodies specific to dupilumab (Dupixent) and the addition of new evolocumab (Repatha), ipilimumab (Yervoy), and secukinumab (Cosentyx) antibodies. These ready-made antibodies are suitable for developing selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for dupilumab, evolocumab, ipilimumab, and secukinumab, and their biosimilars.

Dupilumab limits inflammatory immune responses by targeting IL-4Ra and is approved for treatment of severe atopic eczema. Bio-Rad’s six new anti-dupilumab antibodies can be used to develop PK bridging ELISAs to measure free and total drug, or as a surrogate positive control or reference standard in ADA assays. The range includes two fully human IgG1 clones and four TrailBlazer™ Antibodies with a SpyTag incorporated into their heavy chain, enabling site-directed conjugation or fast switching to a bivalent Fab or a full-length Ig-like format within an hour.

Bio-Rad has also expanded its anti-ipilimumab and anti-secukinumab portfolio to become the first provider of antibodies specific to the drug-target complex, allowing the detection of bound drug. HRP-labeled TrailBlazer antibodies are also now available for evolocumab.

“Bio-Rad’s leading portfolio of monoclonal anti-idiotypic antibodies offers researchers greater flexibility for the development of highly selective and highly sensitive bioanalytical assays,” said Dr. John Cardone, Marketing Manager, Custom Antibodies, Life Science Group, Bio-Rad. “Our drug-target complex binders are unique to Bio-Rad, enabling researchers to detect drugs in the target-bound state, and all our anti-idiotypic antibodies are provided with in-depth data packages for reproducible results.”

These new anti-idiotypic antibodies are approved for in vitro research, for commercial in vitro testing services to support preclinical and clinical drug and biosimilar development, and patient monitoring. To learn more about Bio-Rad’s anti-idiotypic antibodies, visit bio-rad-antibodies.com/anti-idiotypic-antibody.html.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, CA, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,200 employees and $2.8 billion in revenues in 2022. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. For more information, visit bio-rad.com.